Exec-Edge, Author at ExecEdge - Page 20 of 143

Bob’s Discount Furniture 1Q Net Rev +8.5% on New Stores

Bob’s Discount Furniture 1Q Net Rev +8.5% on New Stores

By Daniella Parra Bob’s Discount Furniture, Inc. (NYSE: BOBS) said net revenue in the first quarter increased 8.5% to $578.1 million from a year earlier. Net income in the quarter was $41 million compared to $38.6 million a year earlier...

Shift4 1Q Gross Profit Jumps 54% Amid Global Expansion

Shift4 1Q Gross Profit Jumps 54% Amid Global Expansion

  By Daniella Parra Shift4 Payments, Inc. (NYSE: FOUR) said gross profit rose 54 percent to $370 million in the first quarter from a year earlier. The fintech company supports businesses across industries in more than 75 countries with Asia...

The ONE Group Q1 Operating Income Soars 30% Amid Expansion

The ONE Group Q1 Operating Income Soars 30% Amid Expansion

By Daniella Parra The ONE Group Hospitality, Inc. (Nasdaq: STKS) said first quarter operating income increased 30 percent as its asset-light expansion approach continues to gain traction. The company said it was on track to complete five Grill Concepts conversions...

Portillo’s Q1 Revenue Increases 3.5% Amid Expansion

Portillo’s Q1 Revenue Increases 3.5% Amid Expansion

By Karen Roman Portillo’s Inc. (Nasdaq: PTLO) said first quarter total revenue increased 3.5% to $182.6 million from a year earlier. Net loss was $0.5 million compared to net income of $4.0 million a year prior, and restaurant-level adjusted EBITDA...

Agilent Technologies Names Michael Buckner as CLO

Agilent Technologies Names Michael Buckner as CLO

By Karen Roman Agilent Technologies, Inc. (NYSE: A) said it designated Michael Buckner as Chief Legal Officer, having previously served at Danaher as Vice President, Deputy General Counsel, and Chief M&A Counsel. Mr. Buckner has nearly 30 years of experience...

Glucotrack Shows Long-Term Accuracy of Implantable Glucose Monitor

Glucotrack Shows Long-Term Accuracy of Implantable Glucose Monitor

By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) shared a study highlighting the long-term accuracy of its implantable blood glucose monitoring system as it moves closer to FDA clinical development and eventual commercialization, it said. The results also align with earlier...

Input your search keywords and press Enter.